T he incidence of esophageal adenocarcinoma (EA) arising in Barrett's esophagus, may be increasing, but it is still a rare disease in Japan. 1 We have been following a cohort of patients who had received Helicobacter pylori eradication therapy, [2] [3] [4] [5] and found that cure of H pylori infection may increase the risk of developing reflux esophagitis, 3 an important risk factor for EA. There has been a concern that eradication of H pylori would ultimately result in an increased risk of EA. In the present study, we investigated the incidence of EA in our cohort of Japanese patients cured of H pylori infection.
Patients and Methods
We conducted a retrospective cohort study of 2782 consecutive patients who had endoscopic follow-up after successful eradication therapy for H pylori infection at the outpatient clinic of Nippon Kokan Fukuyama Hospital from June 1995 to July 2015. Cure of infection was confirmed as described previously. 5 After confirmation, the patients underwent follow-up endoscopy yearly.
Twenty-eight patients with gastric cancer and 1 with EA was diagnosed within 1-year of follow-up, and 16 patients had positive urea breath tests noted at 1-year follow-up, suggesting possible recrudescence of H pylori infection. These patients were excluded. The remaining 2737 patients were studied for the development of EA, esophageal squamous cell carcinoma, and gastric cancer. There were 544 women and 2193 men, with a mean age of 53.8 years (range, 20.7-81.4 years).
The study was conducted according to the guidelines of the Declaration of Helsinki. A local ethics committee approved the study protocol, and written informed consent was obtained from each patient.
Results
During the follow-up period of up to 21.4 years (mean, 7.1 years), 2 EAs (0.01% per year), 7 esophageal squamous cell carcinomas (0.04% per year), and 68 gastric cancers (0.35% per year) were identified ( Figure 1 ). The 2 cases of EA were found 5.3 and 12.7 years after H pylori eradication; both were superficial depressed-type in cTNM stage I and were removed by use of endoscopic submucosal resection.
Discussion
The 0.01% incidence rate of EA in our series is lower than rates of 0.04% per year in persons 50 years of age or older with reflux esophagitis 6 and 0.3%-0.6% in patients with nondysplastic Barrett's esophagus 7 in Western countries. However, in contrast to Western countries where the incidence rates of EA had exceeded Clinical Gastroenterology and Hepatology 2018; 16:1995 -1996 the incidence rates of squamous cell cancer, 8 squamous cell carcinoma is a still dominant cancer of the esophagus in Japan. Only 3% of patients with esophageal cancer in Japan have EA. 1 In our study patients, the proportion of EA was nearly 20% among cases with esophageal cancer. Thus, our findings might indicate a higher incidence of EA in patients cured of H pylori infection than in the general population in Japan, even though the incidence is still low. A decrease of gastric cancer and other H pylori-related diseases is expected through eradication of H pylori, but a concomitant increased incidence of reflux esophagitis may be inevitable. 3 Whether and when EA after eradication of H pylori will increase and become a substantial health issue waits long-time further observation in a larger population in Japan.
Our study has two limitations. First, the study was an observational analysis. Second, the incidence of EA itself is still very low in Japan, so the sample size might not be large enough to detect an increased incidence.
In conclusion, this study demonstrated that the incidence of EA after cure of H pylori infection was low in Japan. Thus, concern about increasing the risk of EA by eradicating H pylori may be unfounded. The study also found that the risk of gastric cancer was 0.35% per year, a finding that supports existing evidence that the long-term risk of gastric cancer persists after cure of H pylori infection, 4, 5 and that surveillance endoscopy for gastric cancer after H pylori eradication is warranted. During such surveillance, the esophagus is also examined for EA and esophageal squamous cell carcinoma. Thus, we believe that the benefits associated with eradicating H pylori infection might outweigh the possible increase in EA risk, and that we should not hesitate to recommend H pylori eradication therapy.
